MetaCap

AbbVie Inc. (ABBV)

NYSE: ABBVHealth CareBiotechnology: Pharmaceutical PreparationsUSD

286.20+2.66 (+0.94%)

At close: Nov 20, 4:02 PM ET · Delayed 15 min

ABBV stock chart

Technical analysis

Key statistics

All statistics
Market cap
$505.89B
Dividend yield
2.42% ($6.92)
Ex-dividend date
Oct 15, 2026
52-week range
190.75 – 302.93
Day range
284.85 – 290.23
Volume / Avg
8.76M / 4.84M
Beta
—

52-week range

$190.75$302.93

ABBV stock today

Shares of AbbVie (ABBV) finished higher on Nov 20 at $286.20, a gain of 0.94% or $2.66 per share, versus the S&P 500's 3.70% decline. Shares are 5.5% below their 52-week high of $302.93, set on Nov 5, 2026 and 50.0% above the 52-week low of $190.75, near the top of the past year's range. ABBV is up 25.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.1%.

At 49.2x trailing earnings, AbbVie trades above the peer-group median of 35.8x. Its forward P/E of 17.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. AbbVie pays an annual dividend of $6.92 per share, a 2.42% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About AbbVie

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Robert A. Michael CPA
Headquarters
North Chicago, IL
Employees
57,000
IPO year
2012
Website
abbvie.com

Financial highlights

Full financials

In fiscal 2025, AbbVie generated $61.16 billion in revenue, up 8.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $4.23 billion (-1.2% year over year), for a net margin of 6.9% versus a median of 10.1% in the prior 5 years. Gross margin was 70.2% (up from 70.0%) and operating margin 24.6%.

AbbVie annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$61.16B$56.33B$54.32B$58.05B$56.20B
Growth+8.57%+3.71%-6.44%+3.30%+22.69%
Net income$4.23B$4.28B$4.86B$11.84B$11.54B
EPS (diluted)$2.36$2.39$2.72$6.63$6.45

Analyst forecast

Forecast

Consensus (29 analysts)

buy

Avg. price target

$314.12+9.76%

  • Strong buy 7
  • Buy 16
  • Hold 5
  • Sell 0
  • Strong sell 1

Target range

Low $237.00High $350.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 30, 2026
EPS actual vs est.
$1.86 vs $3.74
Surprise
-50.27%

Dividends

Dividend history
Annual dividend
$6.92
Last payment
$1.73
Ex-dividend date
Oct 15, 2026

ABBV news

All ABBV news

AbbVie peers

Health Care sector
ABBV peer companies
CompanyPrice% ChgMarket capCompare
JNJJohnson & Johnson270.47+1.25%$651.11Bvs ABBV
MRKMerck & Company Inc.133.72+0.69%$329.65Bvs ABBV
NVSNovartis AG150.47-0.50%$284.18Bvs ABBV
AZNAstraZeneca PLC174.35-0.60%$270.40Bvs ABBV
ABTAbbott Laboratories103.00-0.84%$178.39Bvs ABBV
NVONovo Nordisk A/S37.82-2.70%$166.69Bvs ABBV
PFEPfizer Inc.27.40-0.51%$156.18Bvs ABBV
VRTXVertex Pharmaceuticals Incorporated515.02-1.08%$130.58Bvs ABBV

Indexes, lists and sector

AbbVie stock FAQ

What is AbbVie's stock price today?

ABBV last traded at $286.20 as of Nov 20, 4:02 PM EST, up 0.94% on the day. Prices are delayed at least 15 minutes.

Does AbbVie pay a dividend?

Yes. AbbVie pays $6.92 per share annually, a 2.42% yield. The most recent dividend of $1.73 had an ex-dividend date of Oct 15, 2026.

What is ABBV's P/E ratio?

ABBV trades at a trailing P/E ratio of 49.18 and a forward P/E of 17.65, compared with a median of 35.8 for its closest peers.

Is AbbVie in the S&P 500?

Yes. AbbVie (ABBV) is a constituent of the S&P 500 index.

Who is AbbVie's CEO?

Mr. Robert A. Michael CPA is the chief executive officer of AbbVie Inc., which has about 57,000 employees.

What is the ABBV 52-week high?

The 52-week high for ABBV is $302.93 and the 52-week low is $190.75. The stock is currently 5.5% below its high.

Compare ABBV